Puma Biotechnology (NASDAQ:PBYI – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Institutional & Insider Ownership
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for Puma Biotechnology and Aurinia Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Puma Biotechnology | 0 | 2 | 0 | 0 | 2.00 |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
Volatility and Risk
Puma Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Profitability
This table compares Puma Biotechnology and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Puma Biotechnology | 11.50% | 20.76% | 13.22% |
| Aurinia Pharmaceuticals | 100.84% | 26.11% | 19.89% |
Earnings & Valuation
This table compares Puma Biotechnology and Aurinia Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Puma Biotechnology | $228.40 million | 2.24 | $31.11 million | $0.52 | 19.10 |
| Aurinia Pharmaceuticals | $283.05 million | 7.62 | $287.20 million | $2.29 | 7.08 |
Aurinia Pharmaceuticals has higher revenue and earnings than Puma Biotechnology. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Puma Biotechnology on 12 of the 15 factors compared between the two stocks.
About Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
